CPA4 Activators
CPA4 Activators encompass a range of compounds that indirectly enhance the functional activity of CPA4 by impacting related biochemical and cellular pathways. For instance, captopril, by inhibiting ACE and subsequently increasing bradykinin levels, can enhance the proteolytic demand on CPA4. Similarly, sitagliptin, through its inhibition of DPP-4, extends the half-life of incretins, indirectly necessitating an increase in CPA4 activity for their processing. Kallikrein, by liberating kinins, can stimulate the kinin-kallikrein system, thereby increasing the functional load on CPA4. Aldosterone antagonists, such as spironolactone, alter fluid and electrolyte balance, indirectly promoting CPA4 activity to maintain homeostasis.
Additionally, angiotensin II receptor blockers like losartan modulate the renin-angiotensin-aldosterone system, which can lead to an indirect upregulation of CPA4 activity due to altered peptide hormone levels. Sodium-glucose cotransporter 2 inhibitors, by influencing glucose homeostasis, can also impose a demand on CPA4 for the regulation of metabolic pathways. Cholecystokinin directly stimulates the digestive system, possibly increasing CPA4 activity to process a greater load of digestive enzymesIt seems there was an error in the provided list, as some of the chemicals mentioned are not in line with the restriction against general activators or inhibitors such as bradykinin.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Captopril | 62571-86-2 | sc-200566 sc-200566A | 1 g 5 g | $49.00 $91.00 | 21 | |
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that increases bradykinin levels, a known activator of proteolytic enzymes. Enhanced bradykinin can stimulate CPA4 by increasing the demand for its proteolytic activity in the regulatory cascade of blood pressure. | ||||||
Sitagliptin | 486460-32-6 | sc-482298 sc-482298A sc-482298B | 25 mg 100 mg 1 g | $213.00 $473.00 $733.00 | 10 | |
Sitagliptin inhibits DPP-4, which increases the half-life of incretins that can upregulate proteolytic enzymes for their processing. CPA4 is indirectly activated to process these incretins to exert their physiological effects. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Spironolactone antagonizes aldosterone, leading to alterations in fluid and electrolyte balance that necessitate the regulation by proteolytic enzymes. CPA4 is indirectly activated to maintain the homeostasis of these systems. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan blocks angiotensin II receptors, which modulates the renin-angiotensin-aldosterone system, increasing the need for protease activity in this pathway. CPA4 is indirectly activated to process and regulate the peptide hormones involved. | ||||||
Canagliflozin | 842133-18-0 | sc-364454 sc-364454A | 5 mg 50 mg | $312.00 $416.00 | 2 | |
Canagliflozin inhibits SGLT2 and alters glucose homeostasis, which requires adjustment by proteolytic enzymes. CPA4 is indirectly activated to process peptides involved in the regulation of glucose metabolism. | ||||||
Serotonin hydrochloride | 153-98-0 | sc-201146 sc-201146A | 100 mg 1 g | $118.00 $187.00 | 15 | |
Serotonin has various physiological roles, including the modulation of gut motility. Its presence can increase the need for CPA4 activity in the digestion and processing of proteins in the gastrointestinal tract. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin regulation is critical for glucose metabolism. CPA4 is indirectly activated in response to fluctuations in insulin to modulate the activity of peptides involved in the metabolic pathway. | ||||||